SILVER SPRING, Md., June 12 /PRNewswire-FirstCall/ -- Lung Rx, Inc., a wholly-owned subsidiary of United Therapeutics Corporation (Nasdaq: UTHR - News), today announced the FDA response to a protocol amendment request for its ongoing TRIUMPH (TReprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension) study.
